Cargando…

Dynamics of Gut Microbiota and Clinical Variables after Ketogenic and Mediterranean Diets in Drug-Naïve Patients with Type 2 Diabetes Mellitus and Obesity

Type 2 diabetes mellitus (T2DM), the most common form of diabetes, is a progressive chronic metabolic disease that has increasingly spread worldwide, enhancing the mortality rate, particularly from cardiovascular diseases (CVD). Lifestyle improvement through diet and physical activity is, together w...

Descripción completa

Detalles Bibliográficos
Autores principales: Deledda, Andrea, Palmas, Vanessa, Heidrich, Vitor, Fosci, Michele, Lombardo, Mauro, Cambarau, Giulia, Lai, Alessio, Melis, Marietta, Loi, Elisabetta, Loviselli, Andrea, Manzin, Aldo, Velluzzi, Fernanda
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693465/
https://www.ncbi.nlm.nih.gov/pubmed/36355175
http://dx.doi.org/10.3390/metabo12111092
_version_ 1784837549309558784
author Deledda, Andrea
Palmas, Vanessa
Heidrich, Vitor
Fosci, Michele
Lombardo, Mauro
Cambarau, Giulia
Lai, Alessio
Melis, Marietta
Loi, Elisabetta
Loviselli, Andrea
Manzin, Aldo
Velluzzi, Fernanda
author_facet Deledda, Andrea
Palmas, Vanessa
Heidrich, Vitor
Fosci, Michele
Lombardo, Mauro
Cambarau, Giulia
Lai, Alessio
Melis, Marietta
Loi, Elisabetta
Loviselli, Andrea
Manzin, Aldo
Velluzzi, Fernanda
author_sort Deledda, Andrea
collection PubMed
description Type 2 diabetes mellitus (T2DM), the most common form of diabetes, is a progressive chronic metabolic disease that has increasingly spread worldwide, enhancing the mortality rate, particularly from cardiovascular diseases (CVD). Lifestyle improvement through diet and physical activity is, together with drug treatment, the cornerstone of T2DM management. The Mediterranean diet (MD), which favors a prevalence of unprocessed vegetable foods and a reduction in red meats and industrial foods, without excluding any food category, is usually recommended. Recently, scientific societies have promoted a very low-calorie ketogenic diet (VLCKD), a multiphasic protocol that limits carbohydrates and then gradually re-introduces them, with a favorable outcome on body weight and metabolic parameters. Indeed, gut microbiota (GM) modifications have been linked to overweight/obesity and metabolic alterations typical of T2DM. Diet is known to affect GM largely, but only a few studies have investigated the effects of VLCKD on GM, especially in T2DM. In this study, we have compared anthropometric, biochemical, lifestyle parameters, the quality of life, and the GM of eleven patients with recently diagnosed T2DM and overweight or obesity, randomly assigned to two groups of six and five patients who followed the VLCKD (KETO) or hypocaloric MD (MEDI) respectively; parameters were recorded at baseline (T0) and after two (T2) and three months (T3). The results showed that VLCKD had more significant beneficial effects than MD on anthropometric parameters, while biochemical improvements did not statistically differ. As for the GM, despite the lack of significant results regarding the alpha and beta diversity, and the Firmicutes/Bacteroidota ratio between the two groups, in the KETO group, a significant increase in beneficial microbial taxa such as Verrucomicrobiota phylum with its members Verrucomicrobiae, Verrucomicrobiales, Akkermansiaceae, and Akkermansia, Christensenellaceae family, Eubacterium spp., and a reduction in microbial taxa previously associated with obesity (Firmicutes and Actinobacteriota) or other diseases (Alistipes) was observed both at T2 and T3. With regards to the MEDI group, variations were limited to a significant increase in Actinobacteroidota phylum at T2 and T3 and Firmicutes phylum at T3. Moreover, a metagenomic alteration linked to some metabolic pathways was found exclusively in the KETO group. In conclusion, both dietary approaches allowed patients to improve their state of health, but VLCKD has shown better results on body composition as well as on GM profile.
format Online
Article
Text
id pubmed-9693465
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-96934652022-11-26 Dynamics of Gut Microbiota and Clinical Variables after Ketogenic and Mediterranean Diets in Drug-Naïve Patients with Type 2 Diabetes Mellitus and Obesity Deledda, Andrea Palmas, Vanessa Heidrich, Vitor Fosci, Michele Lombardo, Mauro Cambarau, Giulia Lai, Alessio Melis, Marietta Loi, Elisabetta Loviselli, Andrea Manzin, Aldo Velluzzi, Fernanda Metabolites Article Type 2 diabetes mellitus (T2DM), the most common form of diabetes, is a progressive chronic metabolic disease that has increasingly spread worldwide, enhancing the mortality rate, particularly from cardiovascular diseases (CVD). Lifestyle improvement through diet and physical activity is, together with drug treatment, the cornerstone of T2DM management. The Mediterranean diet (MD), which favors a prevalence of unprocessed vegetable foods and a reduction in red meats and industrial foods, without excluding any food category, is usually recommended. Recently, scientific societies have promoted a very low-calorie ketogenic diet (VLCKD), a multiphasic protocol that limits carbohydrates and then gradually re-introduces them, with a favorable outcome on body weight and metabolic parameters. Indeed, gut microbiota (GM) modifications have been linked to overweight/obesity and metabolic alterations typical of T2DM. Diet is known to affect GM largely, but only a few studies have investigated the effects of VLCKD on GM, especially in T2DM. In this study, we have compared anthropometric, biochemical, lifestyle parameters, the quality of life, and the GM of eleven patients with recently diagnosed T2DM and overweight or obesity, randomly assigned to two groups of six and five patients who followed the VLCKD (KETO) or hypocaloric MD (MEDI) respectively; parameters were recorded at baseline (T0) and after two (T2) and three months (T3). The results showed that VLCKD had more significant beneficial effects than MD on anthropometric parameters, while biochemical improvements did not statistically differ. As for the GM, despite the lack of significant results regarding the alpha and beta diversity, and the Firmicutes/Bacteroidota ratio between the two groups, in the KETO group, a significant increase in beneficial microbial taxa such as Verrucomicrobiota phylum with its members Verrucomicrobiae, Verrucomicrobiales, Akkermansiaceae, and Akkermansia, Christensenellaceae family, Eubacterium spp., and a reduction in microbial taxa previously associated with obesity (Firmicutes and Actinobacteriota) or other diseases (Alistipes) was observed both at T2 and T3. With regards to the MEDI group, variations were limited to a significant increase in Actinobacteroidota phylum at T2 and T3 and Firmicutes phylum at T3. Moreover, a metagenomic alteration linked to some metabolic pathways was found exclusively in the KETO group. In conclusion, both dietary approaches allowed patients to improve their state of health, but VLCKD has shown better results on body composition as well as on GM profile. MDPI 2022-11-10 /pmc/articles/PMC9693465/ /pubmed/36355175 http://dx.doi.org/10.3390/metabo12111092 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Deledda, Andrea
Palmas, Vanessa
Heidrich, Vitor
Fosci, Michele
Lombardo, Mauro
Cambarau, Giulia
Lai, Alessio
Melis, Marietta
Loi, Elisabetta
Loviselli, Andrea
Manzin, Aldo
Velluzzi, Fernanda
Dynamics of Gut Microbiota and Clinical Variables after Ketogenic and Mediterranean Diets in Drug-Naïve Patients with Type 2 Diabetes Mellitus and Obesity
title Dynamics of Gut Microbiota and Clinical Variables after Ketogenic and Mediterranean Diets in Drug-Naïve Patients with Type 2 Diabetes Mellitus and Obesity
title_full Dynamics of Gut Microbiota and Clinical Variables after Ketogenic and Mediterranean Diets in Drug-Naïve Patients with Type 2 Diabetes Mellitus and Obesity
title_fullStr Dynamics of Gut Microbiota and Clinical Variables after Ketogenic and Mediterranean Diets in Drug-Naïve Patients with Type 2 Diabetes Mellitus and Obesity
title_full_unstemmed Dynamics of Gut Microbiota and Clinical Variables after Ketogenic and Mediterranean Diets in Drug-Naïve Patients with Type 2 Diabetes Mellitus and Obesity
title_short Dynamics of Gut Microbiota and Clinical Variables after Ketogenic and Mediterranean Diets in Drug-Naïve Patients with Type 2 Diabetes Mellitus and Obesity
title_sort dynamics of gut microbiota and clinical variables after ketogenic and mediterranean diets in drug-naïve patients with type 2 diabetes mellitus and obesity
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9693465/
https://www.ncbi.nlm.nih.gov/pubmed/36355175
http://dx.doi.org/10.3390/metabo12111092
work_keys_str_mv AT deleddaandrea dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity
AT palmasvanessa dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity
AT heidrichvitor dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity
AT foscimichele dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity
AT lombardomauro dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity
AT cambaraugiulia dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity
AT laialessio dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity
AT melismarietta dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity
AT loielisabetta dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity
AT loviselliandrea dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity
AT manzinaldo dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity
AT velluzzifernanda dynamicsofgutmicrobiotaandclinicalvariablesafterketogenicandmediterraneandietsindrugnaivepatientswithtype2diabetesmellitusandobesity